dihexa c-met cancer risk Targeting Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications Dihexa: The Truth About the
Dihexa: The Truth About the Most Potent Synaptogenic Peptide Dihexa (PNB 0408) c Met HGFR Activator MedChemExpress Targeting c MET in gastrointestinal tumours: rationale, opportunities and challenges Nature Reviews Clinical Oncology dihexa hgf c met cancer risk HGF c MET pathway in cancer: from molecular characterization to clinical evidence Targeted Inhibition of Hepatocyte Growth
Pay in 4 interest-free payments of $5.61 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



